Molecular Bilayer Structure (e.g., Vesicle, Liposome) Patents (Class 424/1.21)
  • Patent number: 10449193
    Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: October 22, 2019
    Assignee: Signpath Pharma Inc.
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard, Muhammed Majeed
  • Patent number: 10342747
    Abstract: The skin serves as a barrier that protects the body from the external environment and prevents water loss. This barrier function also prevents most hydrophilic or hydrophobic and large molecular weight ingredients (>500 kDa) from penetrating intact skin. Until recently, methods to increase stratum corneum permeability were generally not effective enough to make the stratum corneum so permeable that the barrier posed by the viable epidermis mattered. However, that has now changed with the development of the present embodiment's physical methods and highly optimized chemical formulations, such that we revisited the permeability of the full epidermis with the example embodiment's constructs and not focus only on the stratum corneum. This example embodiment therefore tests the hypothesis that the viable epidermis offers a significant permeability barrier to both small molecules and macromolecules that becomes the rate limiting step.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: July 9, 2019
    Assignee: PPP&C INC.
    Inventor: David A. Richard
  • Patent number: 10322073
    Abstract: The skin serves as a barrier that protects the body from the external environment and prevents water loss. This barrier function also prevents most hydrophilic or hydrophobic and large molecular weight ingredients (>500 kDa) from penetrating intact skin. Until recently, methods to increase stratum corneum permeability were generally not effective enough to make the stratum corneum so permeable that the barrier posed by the viable epidermis mattered. However, that has now changed with the development of the present embodiment's physical methods and highly optimized chemical formulations, such that we revisited the permeability of the full epidermis with the example embodiment's constructs and not focus only on the stratum corneum. This example embodiment therefore tests the hypothesis that the viable epidermis offers a significant permeability barrier to both small molecules and macromolecules that becomes the rate limiting step.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 18, 2019
    Assignee: PPP&C INC.
    Inventor: David A. Richard
  • Patent number: 10322074
    Abstract: The skin serves as a barrier that protects the body from the external environment and prevents water loss. This barrier function also prevents most hydrophilic or hydrophobic and large molecular weight ingredients (>500 kDa) from penetrating intact skin. Until recently, methods to increase stratum corneum permeability were generally not effective enough to make the stratum corneum so permeable that the barrier posed by the viable epidermis mattered. However, that has now changed with the development of the present embodiment's physical methods and highly optimized chemical formulations, such that we revisited the permeability of the full epidermis with the example embodiment's constructs and not focus only on the stratum corneum. This example embodiment therefore tests the hypothesis that the viable epidermis offers a significant permeability barrier to both small molecules and macromolecules that becomes the rate limiting step.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 18, 2019
    Assignee: PPP&C INC.
    Inventor: David A. Richard
  • Patent number: 10307349
    Abstract: The skin serves as a barrier that protects the body from the external environment and prevents water loss. This barrier function also prevents most hydrophilic or hydrophobic and large molecular weight ingredients (>500 kDa) from penetrating intact skin. Until recently, methods to increase stratum corneum permeability were generally not effective enough to make the stratum corneum so permeable that the barrier posed by the viable epidermis mattered. However, that has now changed with the development of the present embodiment's physical methods and highly optimized chemical formulations, such that we revisited the permeability of the full epidermis with the example embodiment's constructs and not focus only on the stratum corneum. This example embodiment therefore tests the hypothesis that the viable epidermis offers a significant permeability barrier to both small molecules and macromolecules that becomes the rate limiting step.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 4, 2019
    Assignee: PPP&C INC.
    Inventor: David A. Richard
  • Patent number: 10213383
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: February 26, 2019
    Assignee: NOVARTIS AG
    Inventors: Gottfried Kraus, Robert Eskes
  • Patent number: 10201500
    Abstract: The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 12, 2019
    Assignee: Washington University
    Inventors: Gregory M. Lanza, Dipanjan Pan
  • Patent number: 10092516
    Abstract: The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: October 9, 2018
    Assignee: THERASYN SENSORS, INC.
    Inventor: Mary P. McCourt
  • Patent number: 10076580
    Abstract: The present invention relates to a new composition comprising gas-filled microvesicles for contrast imaging which are particularly suitable for providing an effective echo response to at least two selected ultrasound waves having different frequencies. Said composition preferably comprises at least two different preparations of gas-filled microvesicles having respective peaks of non-linear echographic response differing by at least 2 MHz to each other, and preferably have respective size distributions with different median sizes. In particular, said preparations preferably have size distributions with respective DV50 values differing from each other by at least 0.5 ?m, more preferably at least 1.0 ?m. Alternatively, said composition has a volume size distribution showing a value of Bowley skewness of 0.16 or higher.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: September 18, 2018
    Assignee: BRACCO SUISSE S.A.
    Inventors: Philippe Bussat, Peter Frinking, Christian Guillot, Michel Schneider
  • Patent number: 10022397
    Abstract: The invention disclosed provides means of inhibiting, ameliorating, and/or treatment of rheumatoid arthritis through the use of Noble gas containing mixtures. In one embodiment, the invention provides means of reducing inflammation and immune associated pathology through administration of Noble gas mixtures. In one specific embodiment, Xenon gas is administered to a patient in need at concentrations and frequencies sufficient to inhibit inflammatory and autoimmune processes. In another embodiment Noble gas mixtures are administered to reduce pain and provide symptomatic relieve to a patient suffering from rheumatoid arthritis. In another embodiment the use of Noble gas containing mixtures is disclosed as a means of reducing joint destruction through inhibition of matrix metalloprotease production and activity.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: July 17, 2018
    Inventors: Vlad Bogin, Thomas Ichim
  • Patent number: 9994682
    Abstract: Novel block copolymers comprising at least one (poly)2-C1-3alkyl-2-oxazoline block and at least one (poly)dimethyl siloxane block, having at least one end group X which includes both an —NH2 group and an —NH— group, have been found to be particularly suitable for forming vesicles. The vesicles may be used to form filtration membranes.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: June 12, 2018
    Assignee: APPLIED BIOMIMETIC A/S
    Inventor: Mariusz Piotr Grzelakowski
  • Patent number: 9987367
    Abstract: The present invention relates to novel hyaluronic acid (HA) hydrogels comprising vesicles loaded with a drug or a protein or a nucleic acid. The new HA hydrogels provide sustain release formulations that are useful for several clinical and surgical applications, including but not limited to ophthalmology (e.g. glaucoma, corneal, ocular inflammatory, vitreoretinal and medical retinal diseases) and dermatological conditions.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: June 5, 2018
    Assignee: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Subramanian Venkatraman, Tina Tzee Ling Howden, Leonardus Kresna Widjaja
  • Patent number: 9925143
    Abstract: There are provided compositions comprising lipidated glycosaminoglycan particles, methods for their preparation and uses thereof for the efficient in-vivo and in-vitro delivery of nucleic acids, such as, siRNA molecules.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 27, 2018
    Assignees: RAMOT AT TEL-AVIV UNIVERSITY LTD., QUIET THERAPEUTICS LTD.
    Inventors: Dan Peer, Evgenia Alpert
  • Patent number: 9920028
    Abstract: The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L3 is a single bond, etc, R3 is alkyl, etc, L1 and L2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: March 20, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Takeshi Kuboyama, Tomohiro Era, Tomoyuki Naoi
  • Patent number: 9901600
    Abstract: The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: February 27, 2018
    Assignee: Children's Medical Center Corporation
    Inventors: S. Alexander Mitsialis, Changjin Lee, Stella Kourembanas
  • Patent number: 9872870
    Abstract: Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: January 23, 2018
    Assignee: University of Notre Dame du Lac
    Inventors: Zihni Basar Bilgicer, Tanyel Kiziltepe Bilgicer, Jonathan Darryl Ashley, Jared Stefanick, Nathan J. Alves, Michael W. Handlogten
  • Patent number: 9856479
    Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: January 2, 2018
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Jing Zhao, Kavitha Sarma, Mark Borowsky, Toshiro Kendrick Ohsumi
  • Patent number: 9856456
    Abstract: A composition comprising a polycationic agent and a polyanionic agent, and kits comprising the composition, is provided. In embodiments, the polyanionic agent is a nucleic acid and the polycationic agent is a modified polyalkyleneimine polymer.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 2, 2018
    Assignee: THERMO FISHER SCIENTIFIC BALTICS UAB
    Inventors: Arunas Lagunavicius, Lolita Zaliauskiene
  • Patent number: 9839700
    Abstract: The invention relates to polymerized micelles of size inferior to 100 nm for in vivo diagnosis, in particular of cancer. The polymerized micelles of the invention comprise a diagnostic agent and an amphiphilic polymer obtainable by the polymerization of an amphiphilic monomer, said monomer comprising: a lipophilic chain comprising a polymerizable vinylic or diacetylenic group, and a hydrophilic head comprising a polyoxyethylene or polyoxypropylene chain. The invention finds application in the pharmaceutical field, in particular.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: December 12, 2017
    Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Eric Doris, Frédéric Duconge, Edmond Gravel, Nicolas Mackiewicz, Bertrand Tavitian
  • Patent number: 9833464
    Abstract: The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: December 5, 2017
    Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: In San Kim, Byung Heon Lee, Maggie J M Lu, Hsiang-Fa Liang, Yi-ju Ko, Ya-Chin Lo, Li-Wen Chang, Ming-Cheng Wei
  • Patent number: 9789214
    Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 17, 2017
    Assignees: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, NATIONAL YANG-MING UNIVERSITY
    Inventors: Hsin-Ell Wang, Chien-Chung Hsia, Mao-Chi Weng, Kun-Liang Lin, Hao-Wen Kao, Chao-Cheng Chen, Kwan-Hwa Chi, Der-Chi Tien, Wuu-Jyh Lin
  • Patent number: 9713591
    Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
    Type: Grant
    Filed: October 11, 2009
    Date of Patent: July 25, 2017
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, LTD.
    Inventors: Yechezkel Barenholz, Rivka Cohen
  • Patent number: 9597406
    Abstract: This invention provides the controlled-release method for a pharmaceutical composition comprising of metals in the drug carrier. The specific chelator is used to trigger the release of active pharmaceutical ingredients from chelating complex micelles. The drug release rate and half-life can also be controlled by manipulating the dosing sequence and the concentration of metal and specific chelator.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: March 21, 2017
    Assignee: ORIGINAL BIOMEDICALS CO., LTD
    Inventors: Chia-Hung Chen, Chau-Hui Wang, John-Son Lin, Tieh-Hsiung Chiu, Jing-Yi Chen, Pi-Hung Liao, Chia-Chi Su, Wei-Chuan Liao
  • Patent number: 9517202
    Abstract: The present invention is directed to phospholipid compositions and methods of preparation of phospholipid depots that are injectable through a fine needle. The phospholipid depots prepared by the methods described herein comprise nanometer-sized phospholipid particles and exhibit a higher degree of structural order compared to compositions prepared by other methods.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: December 13, 2016
    Assignee: LATITUDE PHARMACEUTICALS INC.
    Inventors: Andrew Xian Chen, Hailiang Chen
  • Patent number: 9506103
    Abstract: The invention relates to a procedure for biphasic preparation of liposomes, in the course of which technically simple and cheap mechanical mixing methods are used to commingle non-polar organic phase containing an individual mixture of natural and synthetic phospholipids and polar aqueous (buffer) phase not miscible with it, resulting in a liposome emulsion of a unique structure. Furthermore, the invention comprises embodiments of the procedure related to the in vitro diagnostic use of liposomes prepared in this way, when protein type active components are anchored to the surface of liposome membranes without application of any detergents and non-protein type active components are simply mixed with the liposome emulsion of a unique structure. In one of the possible embodiments of the procedure a Prothrombin Time (PT) reagent is prepared. Another possible embodiment of the procedure is the preparation of an activated partial thromboplastin time (APTT) reagent.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: November 29, 2016
    Assignee: Diagon Ltd.
    Inventors: Jozsef Antal, Zoltan Vajda, Zsuzsanna Takatsy, Beata Nagy, Agnes Jakab, Laslo Jakab
  • Patent number: 9498439
    Abstract: Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: November 22, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Dipanjan Pan
  • Patent number: 9446156
    Abstract: Image enhancing contrast agents for use in diagnostic and/or therapeutic methods, particularly in the form of gas-filled microvesicles, with enhanced stability. The gas-filled microvesicles are stabilized by a layer of amphiphilic material and comprise from 0.15% to 1.0% by moles of a lipid bearing a hydrophilic polymer. The lipid bearing a hydrophilic polymer is preferably a phospholipid linked to polyethyleneglycol.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: September 20, 2016
    Assignee: BRACCO SUISSE S.A.
    Inventors: Stephane Gorgerat, Christian Guillot, Feng Yan
  • Patent number: 9433690
    Abstract: Methods and solutions are describes whereby radiopharmaceutical radium-224 solutions are added complex for scavenging daughter nuclide, which may enhance the overall targeting and reduces uptake of daughter nuclide in normal tissues and cells. This is accomplished without reducing the bone targeting ability of radium. The methods and solutions are convenient to use since the complexation of daughter nuclide can be done in situ in a ready to use radiopharmaceutical solution or, depending on the activity concentration, in a simple kit format by mixing two solutions and store the mixture for typically 1 minute to a few hours before administration to a patient. The use of targeted chelate scavengers for 224Ra daughter nuclide opens up the possibility for using 224Ra based solutions for medical treatments.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: September 6, 2016
    Assignee: SCIENCONS AS
    Inventor: Roy Hartvig Larsen
  • Patent number: 9345718
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 24, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Patent number: 9216154
    Abstract: Supramolecular assemblies for delivering active agents to cancerous or precancerous tissues in a subject are provided. These supramolecular assemblies are also useful in assays for detecting and imaging of cancerous and precancerous cells. The assemblies are protease-sensitive and comprise a peptide linkage containing a protease consensus sequence. The assemblies can be selectively targeted to cancerous tissue where the protease enzymes degrade the peptide linkage thereby releasing the active agents which were physically or mechanically contained in or retained by the supramolecular assembly.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 22, 2015
    Assignee: Kansas State University Research Foundation
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel, Tej B. Shrestha, Hongwang Wang
  • Patent number: 9211286
    Abstract: An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of an organic acid. Preferably the organic acid is a water soluble alkyl carboxylic acid, a polybasic organic acid, or a combination thereof. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: December 15, 2015
    Assignee: Curatek Pharmaceuticals Holding, Inc.
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 9186322
    Abstract: One aspect of the disclosure relates to a new form of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL in aqueous solution. In one embodiment, the present invention is directed to a composition comprising a lipid-complexed active platinum compound, wherein the complex has a lipid to drug (L/D) ratio of less than about 1 by weight, e.g. about 0.10 to 1, wherein the lipid-complexed active platinum compound comprises at least one lipid and at least one active platinum compound. In other embodiments, wherein lipid-complexed active platinum compound has an average volume-weighted diameter of about 0.5 to about 20 microns. In still other embodiments, the composition further comprises a liposome.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: November 17, 2015
    Assignee: Insmed Incorporated
    Inventors: Jin K. Lee, Brian S. Miller, Fangjun Wu, Lawrence T. Boni, Vladimir Malinin
  • Patent number: 9119782
    Abstract: The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: September 1, 2015
    Inventor: Mary P. McCourt
  • Patent number: 9121022
    Abstract: This invention provides polynucleotide molecules and methods for regulating genes in plants, e.g., by providing RNA for systemic regulation of genes. Various aspects of the invention provide polynucleotide molecules and methods for regulating endogenous genes and transgenes in a plant cell and polynucleotide molecules.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: September 1, 2015
    Assignee: Monsanto Technology LLC
    Inventors: Robert D. Sammons, Sergey Ivashuta, Hong Liu, Dafu Wang, Paul C. C. Feng, Andrei Y. Kouranov, Scott E. Andersen
  • Publication number: 20150110713
    Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Anthony Manganaro, Karen Rockwell
  • Publication number: 20150098898
    Abstract: The present disclosure is related to a pharmaceutical composition for detecting human melanoma cells, including: a liposome, a biomolecule having specificity for ?v?3 integrin and a radionuclide. The present disclosure also provides a method using the pharmaceutical composition for detecting human melanoma cells and a kit performing the method. By means of the specificity of the biomolecule for the ?v?3 integrin, the liposome is enabled to have recognition ability and facilitates the interaction between the liposome and a target cell. Therefore, the present disclosure is capable of being widely applied in the field of melanoma diagnosis, lymphatic metastasis detection and post-surgical monitoring, and so on.
    Type: Application
    Filed: June 19, 2014
    Publication date: April 9, 2015
    Inventors: Si-Yen LIU, Sheng-Nan LO, Wan-Chi LEE, Wei-Chuan HSU, Te-Wei LEE
  • Publication number: 20150093328
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Application
    Filed: April 17, 2013
    Publication date: April 2, 2015
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendricks, Samuel Agresta, Helen Lee
  • Patent number: 8986699
    Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing cell death of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: March 24, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, David M. Goldenberg, Chien-Hsing Chang
  • Patent number: 8961949
    Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: February 24, 2015
    Assignee: Japan Science and Technology Agency
    Inventors: Kazunori Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
  • Patent number: 8920774
    Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: December 30, 2014
    Assignee: Riken
    Inventors: Yasuyuki Ishii, Risa Nozawa, Masaru Taniguchi
  • Publication number: 20140377169
    Abstract: An automated synthesis device to produce Re-188-BMEDA solution including: a plurality of reagent vials, three-way solenoid valves, gel filtration columns and micro pumps, and a reaction vial, a product vial, a temporary storage vial, a filter membrane, and a waste vial, wherein the plurality of reagent vials include first reagent vial and second reagent vials being connected to the reaction vial through first micro pump, the third reagent vial and fourth reagent vial being connected to the reaction vial through second micro pump, fifth reagent vial being connected to the reaction vial through third micro pump, and sixth reagent vial being connected to the temporary storage vial through fourth micro pump, wherein the reaction vial is connected to the plurality of gel filtration columns through the micro-pump, respectively. The automated synthesis device is operable with program to upgrade yield and avoid contamination.
    Type: Application
    Filed: June 19, 2013
    Publication date: December 25, 2014
    Inventors: Ming-Hsin Li, Shu-Pei Chiu, Chih-Hsien Chang, Te-Wei Lee
  • Patent number: 8889398
    Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: November 18, 2014
    Assignee: Viroblock SA
    Inventors: Thierry Pelet, Francesca A. Wallach
  • Patent number: 8871724
    Abstract: The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3?X1?- (SEQ ID NO: 1), wherein X1 and X1?- are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3? are independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterized by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-[L/I/V]-[L/I/V]-[K/R] (SEQ ID NO: 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g., myeloablation.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: October 28, 2014
    Assignee: Apim Therapeutics AS
    Inventors: Marit Otterlei, Per Arne Aas, Emadoldin Feyzi
  • Patent number: 8852472
    Abstract: The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: October 7, 2014
    Assignee: Silence Therapeutics GmbH
    Inventors: Oliver Keil, Jörg Kaufmann
  • Patent number: 8846002
    Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: September 30, 2014
    Assignees: The Ohio State University, Immunomedics, Inc.
    Inventors: John C. Byrd, David M. Goldenberg, Hans J. Hansen
  • Publication number: 20140234210
    Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.
    Type: Application
    Filed: July 9, 2012
    Publication date: August 21, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie A. Kramer, Christopher Y. Poon
  • Publication number: 20140234211
    Abstract: Delivery systems based on liposomes functionalized with peptides and chelating agents, for therapy and imaging by selective targeting of tumour cells expressing the receptors GRP, BB1, BB2, BB3 e BB4 and any other receptor which recognizes the bombesin peptide or analogues thereof are described. In particular, the liposomes contain within them cytotoxic drugs, such as for example doxorubicin, for target-selective antitumour therapy, and, through the presence of the chelating agent, can contain radioactive or paramagnetic ions for the real time visualization of the tumour cells. The liposomes described in this invention thus act as a selective delivery system for drugs and/or contrast agents onto tumour cells expressing the receptors for the class of known peptides such as bombesin (endogenous sequence, analogous or peptidomimetic peptides, agonists or non agonists).
    Type: Application
    Filed: September 28, 2012
    Publication date: August 21, 2014
    Inventors: Antonella Accardo, Diego Tesauro, Giancarlo Morelli, Carlo Pedone, Giuseppe De Rosa, Giuseppina Salzano
  • Publication number: 20140227174
    Abstract: Compositions that facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells are provided. In some embodiments, the compositions include a peptide, an active agent, and a carrier that includes the active agent, wherein the peptide has an amino acid sequence set forth in any of SEQ ID NOs: 1-18; the peptide is associated with and/or conjugated to the active agent, the carrier, or both; the carrier is selected from the group consisting of a micelle, a liposome, an ethosome, and combinations thereof; and the composition is capable of penetrating a stratum corneum (SC) layer when contacted therewith or penetrating a cell when contacted therewith, and optionally wherein the composition further includes one or more free peptides having an amino acid sequence set forth in any of SEQ ID NOs: 1-18.
    Type: Application
    Filed: February 11, 2013
    Publication date: August 14, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CONVOY THERAPEUTICS
    Inventors: John A. Muraski, Samir Mitragotri, Ming Chen
  • Publication number: 20140227175
    Abstract: The invention relates to Cathepsin-binding compounds bound to a carrier comprising a diagnostic moiety, for use in the diagnosis of inflammatory diseases, and/or for use in the diagnosis of neoplastic diseases, wherein the Cathepsin-binding compound binds to inflammatory cells of the tumour stroma. The invention also relates to Cathepsin B-targeting compounds and Cathepsin B-binding and liposome-binding compounds.
    Type: Application
    Filed: June 22, 2012
    Publication date: August 14, 2014
    Applicant: J. Stefan Institute
    Inventors: Olga Vasiljeva, Georgy Mikhaylov, Boris Turk, Norbert Schaschke
  • Publication number: 20140193330
    Abstract: There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent from the carrier. The carriers of the present invention are lipid based or polymer based the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal.
    Type: Application
    Filed: March 12, 2014
    Publication date: July 10, 2014
    Applicant: University Health Network
    Inventors: David JAFFRAY, Christine ALLEN, Jinzi ZHENG, Raymond Matthew REILLY, Gregory Jason PERKINS